Quinupristin-Dalfopristin Complex (mesylate)
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Quinupristin-Dalfopristin Complex is a mixture of two streptrogramin antibiotics.
Quinupristin-dalfopristin complex is a mixture of two streptrogramin antibiotics, dalfopristin and quinupristin. Streptogramin antibiotics are divided into types A and B, which in combination can act synergistically.
In vitro: A previous study compared the molecular interactions of the streptogramin combinations Synercid (type A, dalfopristin; type B, quinupristin) and NXL 103 (type A, flopristin; type B, linopristin) with the Escherichia coli 70S ribosome. Results showed that the streptogramin A and B components in Synercid and NXL 103 exhibited synergistic antimicrobial activity against certain pathogenic bacteria. Moreover, in transcription-coupled translation assays, only combinations including dalfopristin, the streptogramin A component of Synercid, showed synergy [1].
In vivo: A previous animal study aimed to investigate the efficacy of quinupristin/dalfopristin in the prevention of prosthetic graft infection in a rat subcutaneous pouch model. Results showd that quinupristin/dalfopristin had a significantly higher efficacy than levofloxacin and doxycycline. In addition, only the group treated with quinupristin/dalfopristin combined with levofloxacin or doxycycline showed no evidence of staphylococcal infection [2].
Clinical trial: In a randomized multicentric trial comparing Synercid with vancomycin for the treatment of nosocomial pneumonia due to gram-positive cocci, the cure rate (56.3% vs 58.3%) were equivalent in the 2 treatment arms. Treatment failures were also similar: 44% vs 42%. Mortality (25% vs 22%) was likewise comparable, as was tolerance [3].
References:
[1] Noeske, J. ,Huang, J.,Olivier, N.B., et al. Synergy of streptogramin antibiotics occurs independently of their effects on translation. Antimicrobial Agents and Chemotherapy 58(9), 5269-5279 (2014).
[2] Ghiselli R, Giacometti A, Cirioni O, Mocchegiani F, Orlando F, Del Prete M, D'Amato G, Scalise G, Saba V. Quinupristin/dalfopristin bonding in combination with intraperitoneal antibiotics prevent infection of knitted polyester graft material in a subcutaneous rat pouch model infected with resistant Staphylococcus epidermidis. Eur J Vasc Endovasc Surg. 2002 Sep;24(3):230-4.
[3] Potel G. Value of Synercid in clinical practice: from temporary approval to clinical trial authorization. Presse Med. 2001 Sep 8;30(25 Pt 2):XIX-XXII.
| Physical Appearance | A solid |
| Storage | Store at -20°C |
| M.Wt | 1905.3 |
| Formula | C34H51N4O9S[CH3SO3]·C53H68N9O10S[CH3SO3] |
| Synonyms | RP 59500 |
| Solubility | Soluble in ethanol;methanol;DMSO;dimethyl formamide |
| Chemical Name | 4-[4-(dimethylamino)-N-methyl-L-phenylalanine]-5-[(2S)-5-[(1-azabicyclo[2.2.2]oct-3-ylthio)methyl]-4-oxo-2-piperidinecarboxylic acid]-virginiamycin S1, monomethanesulfonate mixture with (3R,4R,5E,10E,12E,14S,26R,26aS)-26-[[2-(diethylamino)ethyl |
| SDF | Download SDF |
| Canonical SMILES | O=C1C[C@]([H])(N(C[C@H]1CS[C@@H]2C[NH+]3CCC2CC3)C([C@@]([H])(N(C([C@@]4(CCCN4C([C@@H](CC)N5)=O)[H])=O)C)CC6=CC=C(C=C6)N(C)C)=O)C(N[C@H](C(O[C@@H]([C@@H](C5=O)NC(C7=C(C=CC=N7)O)=O)C)=O)C8=CC=CC=C8)=O.CS([O-])(=O)=O.O=C(NC/C=C\C(C)=C\[C@H](C9)O)/C=C/[C@H]([ |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
| 细胞实验 [1]： | |
|
细胞系 |
大肠杆菌ATCC 29417（MRE 600），粪肠球菌ATCC 29212，金黄色葡萄球菌ATCC 29213，流感嗜血杆菌ATCC 49247和肺炎链球菌ATCC 49619。 |
|
溶解方法 |
在DMSO中是可溶的。为了获得更高的浓度，可以将离心管在37℃加热10分钟和/或在超声波浴中震荡一段时间。原液可以在-20℃以下储存几个月。 |
|
反应条件 |
1 μg/ml～64 μg/ml |
|
应用 |
在所有其他测试菌株中，flopristin表现出高于dalfopristin的活性，linopristin的活性与quinupristin相同或更低。对于所有菌株，dalfopristin预水解形式给药的MIC值是virginiamycin M的2倍，后者在化学上与dalfopristin的水解产物相同。 |
| 动物实验 [2]： | |
|
动物模型 |
葡萄球菌感染的雄性Wistar大鼠 |
|
剂量 |
50 mg/l quinupristin/dalfopristin浸泡 |
|
应用 |
Quinupristin/dalfopristin疗效显着高于左氧氟沙星和强力霉素，即使是显示细菌生长仅接受quinupristin/dalfopristin浸泡的大鼠定量移植培养物。否则，左氧氟沙星的功效与强力霉素相似。 只有用quinupristin/dalfopristin联合左氧氟沙星或强力霉素治疗的组没有葡萄球菌感染。 |
|
注意事项 |
请测试所有化合物在室内的溶解度，实际溶解度和理论值可能略有不同，这是由实验系统的误差引起的，属于正常现象。 |
|
References: [1]. Noeske J, Huang J, Olivier NB, Giacobbe RA, Zambrowski M, Cate JH. Synergy of streptogramin antibiotics occurs independently of their effects on translation.Antimicrob Agents Chemother. 2014 Sep;58(9):5269-79. doi: 10.1128/AAC.03389-14.Epub 2014 Jun 23. PubMed PMID: 24957822; PubMed Central PMCID: PMC4135883. [2]. Ghiselli R, Giacometti A, Cirioni O, Mocchegiani F, Orlando F, Del Prete M, D'Amato G, Scalise G, Saba V. Quinupristin/dalfopristin bonding in combination with intraperitoneal antibiotics prevent infection of knitted polyester graft material in a subcutaneous rat pouch model infected with resistant Staphylococcus epidermidis. Eur J Vasc Endovasc Surg. 2002 Sep;24(3):230-4. PubMed PMID:12217284. |
|
